The revolutionary ability to transform agriculture and biomedicine gives rise to new societal and environmental considerations. We strive to understand and shape positive impacts of genome editing on society.
The IGI is advancing science policy to ensure genome engineering developments serve the public good.
The Public Impact team engages with policymakers and regulators around the world to establish responsible governance mechanisms.
We facilitate dialogue through outreach to key stakeholders to ensure that genome-editing technology is equitably developed and distributed.
We convene stakeholder communities to discuss applications, risks and benefits. We integrate stakeholder feedback into our research direction to ground our priorities in societal needs.
Our research creates new paradigms for equitable and affordable applications of genome-editing technologies, including investigating new models of commercialization.
Genetic therapies on the market have list prices over $3 million per dose. An IGI-led task force developed a roadmap to deliver affordable genetic therapies with a focus on the role of mission-driven institutions. We empower scientists in low- and middle-income countries to use CRISPR technology to develop products specific to their own needs.
The IGI maximizes its impact around the world by working in close collaboration with a network of global partners in health, climate, and agriculture.